Form 10-Q RAPT Therapeutics, Inc. For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Guggenheim Downgrades Rapt Therapeutics (RAPT) to Neutral
May 9, 2024 4:03 PM EDTGuggenheim analyst Yatin Suneja downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Neutral.
The analyst comments "Key takeaways from our call with RAPT mgmt. include: (1) database cleaning is underway for both atopic dermatitis and asthma studies of RPT-193 (oral CCR4 blocker; recall that in Feb 2024, both clinical studies were put on... More
